Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes

Journal of Medicinal Chemistry

Volumn 46, Issue 14, 2003, Pages 2895-2907

  McGovern, Susan L ^a   Shoichet, Brian K ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; BENZIMIDAZOLE; FOLIC ACID DERIVATIVE; METHOTREXATE; PTERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TOLRESTAT; TRIMETHOPRIM;

ARTICLE; BINDING SITE; CALCULATION; CRYSTALLOGRAPHY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME CONFORMATION; ENZYME STRUCTURE; MOLECULAR MODEL;

ANIMALS; APOENZYMES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DATABASES, PROTEIN; ENZYMES; HOLOENZYMES; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038460858     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0300330     Document Type: Article

References (64)

1. Schnecke, V.; Swanson, C. A.; Getzoff, E. D.; Tainer, J. A.; Kuhn, L. A. Screening a peptidyl database for potential ligands to proteins with side-chain flexibility. Proteins 1995, 33, 74-87.
2. Charifson, P. S.; Corkery, J. J.; Murcko, M. A.; Walters, W. P. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J. Med. Chem. 1999, 42, 5100-5109.
3. Stahl, M.; Rarey, M. Detailed analysis of scoring functions for virtual screening. J. Med. Chem. 2001, 44, 1035-1042.
4. Gschwend, D. A.; Good, A. C.; Kuntz, I. D. Molecular docking towards drug discovery. J. Mol. Recognit. 1996, 9, 175-186.
5. Hoffmann, D.; Kramer, B.; Washio, T.; Steinmetzer, T.; Rarey, M. et al. Two-stage method for protein-ligand docking. J. Med. Chem. 1999, 42, 4422-4433.
6. Abagyan, R.; Totrov, M. High-throughput docking for lead generation. Curr. Opin. Chem. Biol. 2001, 5, 375-382.
7. http://us.expasy.org/sprot/.
8. Wang, G.; Dunbrack, R. L. http://www.fccc.edu/research/labs/dunbrack/pisces/.
9. Enyedy, I. J.; Ling, Y.; Nacro, K.; Tomita, Y.; Wu, X. et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 2001, 44, 4313-4324.
10. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T. et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. 2001, 44, 4615-4627.
11. Schapira, M.; Raaka, B. M.; Samuels, H. H.; Abagyan, R. In silico discovery of novel Retinoic Acid Receptor agonist structures. BMC Struct. Biol. 2001, 1, 1.
12. Zuccotto, F.; Zvelebil, M.; Brun, R.; Chowdhury, S. F.; Di Lucrezia, R. et al. Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase. Eur. J. Med. Chem. 2001, 36, 395-405.
13. Wei, B. Q.; Baase, W. A.; Weaver, L. H.; Matthews, B. W.; Shoichet, B. K. A model binding site for testing scoring functions in molecular docking. J. Mol. Biol. 2002, 322, 339-355.
14. Montgomery, J. A.; Niwas, S.; Rose, J. D.; Secrist, J. A., 3rd; Babu, Y. S. et al. Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-deazaguanine. J. Med. Chem. 1993, 36, 55-69.
15. 9-benzylguanine: A new class of potent purine nucleoside phosphorylase inhibitors. Bioorg. Med. Chem. Lett. 1992, 2, 407-410.
16. Andricopulo, A. D.; Yunes, R. A. Structure-activity relationships for a collection of structurally diverse inhibitors of purine nucleoside phosphorylase. Chem. Pharm. Bull. (Tokyo) 2001, 49, 10-17.
17. Farutin, V.; Masterson, L.; Andricopulo, A. D.; Cheng, J.; Riley, B. et al. Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase. J. Med. Chem. 1999, 42, 2422-2431.
18. Mao, C.; Cook, W. J.; Zhou, M.; Federov, A. A.; Almo, S. C. et al. Calf spleen purine nucleoside phosphorylase complexed with substrates and substrate analogues. Biochemistry 1998, 37, 7135-7146.
19. Griffin, R. J.; Curtin, N. J.; Newell, D. R.; Golding, B. T.; Durkacz, B. W. et al. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 1995, 77, 408-422.
20. Suto, M. J.; Turner, W. R.; Arundel-Suto, C. M.; Werbel, L. M.; Sebolt-Leopold, J. S. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des. 1991, 6, 107-117.
21. White, A. W.; Almassy, R.; Calvert, A. H.; Curtin, N. J.; Griffin, R. J. et al. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J. Med. Chem. 2000, 43, 4084-4097.
22. Ruf, A.; de Murcia, G.; Schulz, G. E. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 1998, 37, 3893-3900.
23. Balasubramanian, B. N., Ed. Advances in the Design and Development of Thrombin Inhibitors; 1995; pp 999-1007.
24. Dev, I. K.; Harvey, R. J. N10-Formyltetrahydrofolate is the formyl donor for glycinamide ribotide transformylase in Escherichia coli. J. Biol. Chem. 1978, 253, 4242-4244.
25. Beardsley, G. P.; Moroson, B. A.; Taylor, E. C.; Moran, R. G. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J. Biol. Chem. 1989, 264, 328-333.
26. Almassy, R. J.; Janson, C. A.; Kan, C. C.; Hostomska, Z. Structures of apo and complexed Escherichia coli glycinamide ribonucleotide transformylase. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 6114-6118.
27. Henderson, D. M.; Hanson, S.; Allen, T.; Wilson, K.; Coulter-Karis, D. E. et al. Cloning of the gene encoding Leishmania donovani S-adenosylhomocysteine hydrolase, a potential target for antiparasitic chemotherapy. Mol. Biochem. Parasitol. 1992, 53, 169-183.
28. Wolos, J. A.; Frendorf, K. A.; Esser, R. E. Immunosuppression mediated by an inhibitor of S-adenosyl-L-homocysteine hydrolase. Prevention and treatment of collagen-induced arthritis. J. Immunol. 1993, 151, 526-534.
29. Wnuk, S. F.; Yuan, C. S.; Borchardt, R. T.; Balzarini, J.; De Clercq, E. et al. Nucleic acid related compounds. 84. Synthesis of 6′-(E and Z)-halohomovinyl derivatives of adenosine, inactivation of S-adenosyl-L-homocysteine hydrolase, and correlation of anticancer and antiviral potencies with enzyme inhibition. J. Med. Chem. 1994, 37, 3579-3587.
30. Urzhumtsev, A.; Tete-Favier, F.; Mitschler, A.; Barbanton, J.; Barth, P. et al. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 1997, 5, 601-612.
31. Stout, T. J.; Stroud, R. M. The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2.0 A resolution: implications for a new mode of inhibition. Structure 1996, 4, 67-77.
32. Kick, E. K.; Roe, D. C.; Skillman, A. G.; Liu, G.; Ewing, T. J. et al. Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. Chem. Biol. 1997, 4, 297-307.
33. Fradera, X.; de la Cruz, X.; Silva, C. H. T. P.; Gelpi, J. L.; Luque, F. J. et al. Ligand-induced changes in the binding sites of proteins. Bioinformatics 2002, 18, 939-948.
34. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N. et al. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
35. Pieper, U.; Eswar, N.; Stuart, A. C.; Ilyin, V. A.; Sali, A. MODBASE, a database of annotated comparative protein structure models. Nucleic Acids Res. 2002, 30, 255-259.
36. Melo, F.; Sanchez, R.; Sali, A. Statistical potentials for fold assessment. Protein Sci. 2002, 11, 430-448.
37. Altschul, S. F.; Madden, T. L.; Schaffer, A. A.; Zhang, J.; Zhang, Z. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25, 3389-3402.
38. Hann, M.; Hudson, B.; Lewell, X.; Lifely, R.; Miller, L. et al. Strategic pooling of compounds for high-throughput screening. J. Chem. Inf. Comput. Sci. 1999, 39, 897-902.
39. Lorber, D. M.; Shoichet, B. K. Flexible ligand docking using conformational ensembles. Protein Sci. 1998, 7, 938-950.
40. Meng, E. C.; Shoichet, B. K.; Kuntz, I. D. Automated docking with grid-based energy evaluation. J. Comput. Chem. 1992, 13, 505-524.
41. Shoichet, B. K.; Bodian, D. L.; Kuntz, I. D. Molecular docking using shape descriptors. J. Comput. Chem. 1992, 13, 380-397.
42. Gilson, M. K.; Honig, B. H. Calculation of electrostatic potentials in an enzyme active site. Nature 1987, 330, 84-86.
43. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
44. Shoichet, B. K.; Kuntz, I. D. Matching chemistry and shape in molecular docking. Protein Eng. 1993, 6, 723-732.
45. Lorber, D. M.; Udo, M. K.; Shoichet, B. K. Protein-protein docking with multiple residue conformations and residue substitutions. Protein Sci. 2002, 11, 1393-1408.
46. Gschwend, D. A.; Kuntz, I. D. Orientational sampling and rigid-body minimization in molecular docking revisited: on-the-fly optimization and degeneracy removal. J. Comput.-Aided Mol. Des. 1996, 10, 123-132.
47. Bolin, J. T.; Filman, D. J.; Matthews, D. A.; Hamlin, R. C.; Kraut, J. Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate. J. Biol. Chem. 1982, 257, 13650-13662.
48. Bystroff, C.; Oatley, S. J.; Kraut, J. Crystal structures of Escherichia coli dihydrofolate reductase: the NADP+ holoenzyme and the folate. NADP+ ternary complex. Substrate binding and a model for the transition state. Biochemistry 1990, 29, 3263-3277.
49. Fedorov, A.; Shi, W.; Kicska, G.; Fedorov, E.; Tyler, P. C. et al. Transition state structure of purine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis. Biochemistry 2001, 40, 853-860.
50. Kapples, K. J.; Shutske, G. M.; Bores, G. M.; Huger, F. P. Synthesis and in vitro acetylcholinesterase inhibitory activity of some 1-substituted analogues of velnacrine. Bioorg. Med. Chem. Lett. 1993, 3, 2789-2792.
51. Skrzypczak-Jankun, E.; Carperos, V. E.; Ravichandran, K. G.; Tulinsky, A.; Westbrook, M. et al. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J. Mol. Biol. 1991, 221, 1379-1393.
52. Greasley, S. E.; Yamashita, M. M.; Cai, H.; Benkovic, S. J.; Boger, D. L. et al. New insights into inhibitor design from the crystal structure and NMR studies of Escherichia coli GAR transformylase in complex with beta-GAR and 10-formyl-5, 8, 10-trideazafolic acid. Biochemistry 1999, 38, 16783-16793.
53. Turner, M. A.; Yuan, C. S.; Borchardt, R. T.; Hershfield, M. S.; Smith, G. D. et al. Structure determination of selenomethionyl S-adenosylhomocysteine hydrolase using data at a single wavelength. Nat. Struct. Biol. 1998, 5, 369-376.
54. Hu, Y.; Komoto, J.; Huang, Y.; Gomi, T.; Ogawa, H. et al. Crystal structure of S-adenosylhomocysteine hydrolase from rat liver. Biochemistry 1999, 38, 8323-8333.
55. Wilson, D. K.; Bohren, K. M.; Gabbay, K. H.; Quiocho, F. A. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science 1992, 257, 81-84.
56. Dvir, H.; Wong, D. M.; Harel, M.; Barril, X.; Orozco, M. et al. 3D structure of Torpedo californica acetyleholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. Biochemistry 2002, 41, 2970-2981.
57. Kamb, A.; Finer-Moore, J.; Calvert, A. H.; Stroud, R. M. Structural basis for recognition of polyglutamyl folates by thymidylate synthase. Biochemistry 1992, 31, 9883-9890.
58. Stout, T. J.; Sage, C. R.; Stroud, R. M. The additivity of substrate fragments in enzyme-ligand binding. Structure 1998, 6, 839-848.
59. Gangjee, A.; Yu, J.; McGuire, J. J.; Cody, V.; Galitsky, N. et al. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent. J. Med. Chem. 2000, 43, 3837-3851.
60. Li, J.-H.; Tays, K. L.; Zhang, J. Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity. In PCT Intl. Appl., 1999.
61. Karlsson, O.; Linschoten, M.; Nystrom, J.-E. New amidino derivatives and their use as thrombin inhibitors. PCT Intl. Appl., 1998.
62. Habeck, L. L.; Leitner, T. A.; Shackelford, K. A.; Gossett, L. S.; Schultz, R. M. et al. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res. 1994, 54, 1021-1026.
63. Narayanan, S. R.; Keller, B. T.; Borcherding, D. R.; Scholtz, S. A.; Borchardt, R. T. 9-(trans-2′,trans-3′-Dihydroxycyclopent-4′enyl) derivatives of adenine and 3-deazaadenine: potent inhibitors of bovine liver S-adenosylhomocysteine hydrolase. J. Med. Chem. 1988, 31, 500-503.
64. Malamas, M. S.; Sestanj, K.; Millen, J. Naphthalenylsulfonylhydantoins as aldose reductase inhibitors. Eur. J. Med. Chem. 1991, 26, 369-374.